Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Aim: When selecting treatments for type 2 diabetes (T2D), it is important to consider not only efficacy and safety, but also other treatment attributes that have an impact on patient preference. The objective of this study was to examine preference between injection devices used for two weekly GLP‐1 receptor agonists. Materials and Methods: The PREFER study was an open‐label, multicentre, randomized, crossover study assessing patient preference for dulaglutide and semaglutide injection devices among injection‐naïve patients receiving oral medication for type 2 diabetes. After being trained to use each device, participants performed all steps of injection preparation and administered mock injections into an injection pad. Time‐to‐train (TTT) for each device was assessed in a subset. Results: There were 310 evaluable participants (48.4% female; mean age, 60.0 years; 78 participants in the TTT subgroup). More participants preferred the dulaglutide device than the semaglutide device (84.2% vs. 12.3%; P < 0.0001). More participants perceived the dulaglutide device to have greater ease of use (86.8% vs. 6.8%; P < 0.0001). After preparing and using the devices, more participants were willing to use the dulaglutide device (93.5%) than the semaglutide device (45.8%). Training participants to use the dulaglutide device required less time than the semaglutide device (3.38 vs. 8.14 minutes; P < 0.0001). Conclusions: Participants with type 2 diabetes preferred the dulaglutide injection device to the semaglutide injection device. If patients prefer a device, they may be more willing to use the medication, which could result in better health outcomes. Furthermore, a shorter training time for injection devices may be helpful in busy clinical practice settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486
Wysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., & Lakshmanan, M. (2014) · Diabetes Care · doi:10.2337/dc13-2760 · Cited by 396
Nauck, M., Weinstock, R. S., Umpierrez, G. E., Guerci, B., Skrivanek, Z., & Milicevic, Z. (2014) · Diabetes Care · doi:10.2337/dc13-2761 · Cited by 284
GLP-1 receptor agonists: a review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Ellis, S. L. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814559725 · Cited by 282
Giorgino, F., Benroubi, M., Sun, J.-H., Zimmermann, A. G., & Pechtner, V. (2015) · Diabetes Care · doi:10.2337/dc14-1625 · Cited by 268
Ludvik, B., Frías, J. P., Tinahones, F. J., Wainstein, J., Jiang, H., Robertson, K. E., García-Pérez, L.-E., Woodward, D. B., & Milicevic, Z. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30023-8 · Cited by 266
Self-citationNauck, M. A., Petrie, J. R., Sesti, G., Mannucci, E., Courrèges, J.-P., Lindegaard, M. L., Jensen, C. B., & Atkin, S. L. (2016) · Diabetes Care · doi:10.2337/dc15-0165 · Cited by 233
Cited by
GLP-1 receptor agonists: an updated review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Smith, B. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018821997320 · Cited by 289
Morieri, M. L., Rigato, M., Frison, V., Simioni, N., D'Ambrosio, M., Tadiotto, F., Paccagnella, A., Lapolla, A., Avogaro, A., & Fadini, G. P. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154190 · Cited by 31
Mody, R., Manjelievskaia, J., Marchlewicz, E. H., Malik, R. E., Zimmerman, N. M., Irwin, D. E., & Yu, M. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.01.017 · Cited by 22
Self-citationInstituting a successful discharge plan for patients with type 2 diabetes: challenges and solutions
Demidowich, A. P., Batty, K., & Zilbermint, M. (2022) · Diabetes Spectrum · doi:10.2337/dsi22-0013 · Cited by 15
Kushner, P., Anderson, J. E., Simon, J., Boye, K. S., Ranta, K., Torcello-Gómez, A., & Levine, J. A. (2023) · Clinical Diabetes · doi:10.2337/cd22-0029 · Cited by 14
Self-citation
Metadata
- Authors
- Matza, L. S., Boye, K. S., Stewart, K. D., Coyne, K. S., Wullenweber, P. K., Cutts, K. N., Jordan, J. B., Wang, Q., Yu, M., Currie, B. M., Malley, K. G., Ishak, K. J., Hietpas, R. T., & García‐Pérez, L.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2019-12-19
- Volume
- 22
- Issue
- 3
- Pages
- 355-364
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2982236336
- Cited by
- 46
- References
- 14
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.